Everything below concerns melanocortin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-10. Numbers and descriptions here follow the published literature rather than marketing material.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
== Complications == LA-ICP-MS function optimally with gold particles greater than 60 μm in diameter to avoid any contamination during measurements. Although LA-ICP-MS has a lower detection limit, its overall precision was lower than other analysis techniques for trace element concentrations such as field emission-electron probe microanalysis (FE-EPMA) and synchrotron micro X-ray fluorescence spectroscopy (SR-l-XRF). Due to the small size of gold (<5μm-250μm) small fragments of minerals need to be separated from the gold before analysis can occur. Gold fingerprinting has limitations including elemental fractionation (the non-sample related analyte) and calibration requires matrix-matched standards. A few other problems exist that limit actual sourcing or provencancing of gold in relation to manufactured art objects. These problems include: a lack of an extensive database of elemental profiles in gold ores, the natural differences that coexist in ore geology and the difficulties of accurately analyzing trace elements. Also, trading, looting and re-melting of so called “precious” metal objects add to the problem of sourcing.
=== COVID-19 === At the start of the COVID-19 pandemic, some doctors observed that anecdotally some hospitalized patients in China may have had better outcomes on famotidine than other patients who were not taking famotidine. This led to hypotheses about use of famotidine in treatment of COVID-19. Famotidine was considered a possible treatment for COVID-19 due to its potential anti-inflammatory effects. It was thought that famotidine could modify lung inflammation caused by coronaviruses. However, studies have shown that famotidine is not effective in reducing mortality or improving recovery in COVID-19 patients. Famotidine primarily works by blocking the effects of histamine and has some potential mechanisms of action that may contribute to its anti-inflammatory properties, including the inhibition of the production of certain pro-inflammatory cytokines such as TNF-alpha and IL-6. Another hypothesis was that famotidine might activate the vagus nerve inflammatory reflex to attenuate cytokine storm. Yet another hypothesis was that famotidine can reduce the activation of mast cells and the subsequent release of inflammatory mediators, therefore acting as a mast cell stabilizer. However, while famotidine may have some anti-inflammatory effects, there is currently insufficient evidence to support its use for treating inflammation associated with COVID-19. Therefore, it is not recommended for this purpose.
A typical 10-in-1 food parcel included canned items as butter-substitute spread, soluble coffee, pudding, meat units, jam, evaporated milk, and vegetables as well as biscuits, cereal, beverages, candy, salt, and sugar.
== Advantages == Shotgun proteomics allows global protein identification as well as the ability to systematically profile dynamic proteomes. It also avoids the modest separation efficiency and poor mass spectral sensitivity associated with intact protein analysis.
=== Filming === Filming began with the first round, which was shot through July 18–22, 2024, inside of Allegiant Stadium in Las Vegas, with a total of 2,000 contestants attending. This round is released on YouTube. The Beast City part of the competition that was featured in the first four, sixth, eighth and ninth episode of the TV series as well as a second YouTube video promoting the series featuring 20 eliminated contestants competing for $500,000, was filmed with the remaining 1,000 contestants at Downsview Park Studios in Toronto, Ontario, Canada, in August of that year. The "Beast Island" part of the competition featured in the fourth to sixth episodes, along with the tenth episode of the show was filmed at the uninhabited La Vivienda Island, which is located in the Pearl Islands, Panama. The filming broke 44 Guinness World Records, including the largest physical cash prize on set ($5,000,000), the most prize money turned down on a competitive reality TV show ($1,000,000), the largest prize fund awarded for a competitive reality TV show ($10,000,000), and the most money won in a single episode of a competitive reality TV show ($2,020,000), and a page in the 2026 Guinness Book of World Records was focused on the show.
Sources: en.wikipedia.org
At 10 Downing Street in early September 1964, impasse developed between Douglas-Home and Smith over the best way to measure black public opinion in Southern Rhodesia. A key plank of Britain's Southern Rhodesia policy was that the terms for independence had to be "acceptable to the people of the country as a whole"—agreeing to this, Smith suggested that white and urban black opinion could be gauged through a general referendum of registered voters, and that rural black views could be obtained at a national indaba (tribal conference) of chiefs and headmen. Douglas-Home told Smith that although this proposal satisfied him personally, he could not accept it as he did not believe the Commonwealth, the United Nations or the Labour Party would also do so. He stressed that such a move towards accommodation with Smith might hurt the Conservatives' chances in the British general election the next month, and suggested that it might be in Smith's best interests to wait until after the election to continue negotiations. Smith accepted this argument. Douglas-Home assured Smith that a Conservative government would settle with him and grant independence within a year. Attempting to form a viable white opposition to the Rhodesian Front, the UFP resurrected itself around Welensky, renamed itself the Rhodesia Party, and entered the Arundel and Avondale by-elections that had been called for 1 October 1964.
=== Competitive and ecological roles === Beyond these interactions, Xanthoria parietina often overgrows other epilithic lichens without affecting their photobionts. It also supports microbial communities beneath its thallus, likely benefiting from microhabitats created by its attachment structures. In addition, Xanthoria parietina plays a role in biogeochemical cycling by promoting rock weathering through hyphal penetration and adhesion. Its interactions with minerals such as quartz, feldspar, and muscovite contribute to mineral breakdown, particularly in carbonate-rich substrates. Finally, the lichen competes with other foliose lichens. In experimental settings, it showed competitive equivalence with Parmelia caperata but was overgrown by Parmelia saxatilis under some conditions. In three-species mixtures, however, X. parietina often gained a competitive advantage—possibly due to its tolerance for elevated nitrogen levels. Its ability to thrive in nutrient-rich environments may allow it to outcompete acidophytic species in habitats influenced by agricultural or atmospheric nitrogen inputs. When competing with other lichens, X. parietina typically forms codominant relationships rather than completely displacing other species, particularly in early colonization stages. Field studies show that when X. parietina thalli border upon other lichens such as Physcia species, neither distinctly overgrows the other, but rather their marginal lobes intermingle. The frequent co-occurrence of X. parietina with grey-colored Physcia species may represent more than simple cohabitation.
==== FogPharma ==== In 2016, Verdine co-founded FogPharma with Sir David Lane to develop next-generation stapled peptides, Cell-Penetrating Miniproteins (CPMPs), a broad new class of medicines that aim to combine the cell-penetrating abilities of small molecules with the strong target engagement of biologics. In 2024, FogPharma was rebranded to Parabilis Medicines.
The main secondary aspect of the Discipline is that the avout are allowed to own only their "bolt, chord, and sphere". These objects are made with "newmatter" (matter made with a modified atomic structure to be more versatile), and can be made to alter their shape, texture and other physical properties without the use of tools or other outside technologies. The bolt is a length of newmatter fabric and is used as clothing; the chord is a newmatter rope used to secure the bolt; and the sphere is a newmatter balloon of adjustable size, shape and hardness, and serves as a multipurpose tool. There are several restrictions governing, for example, the use of "sequencing" (genetic engineering), "syntactic devices" (computers), or other "praxis" (technology). Due to the restrictions, avout can only work on an entirely theoretical basis de jure.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.